Insights into significance of combined inhibition of MEK and m-TOR signalling output in KRAS mutant non-small-cell lung cancer

被引：0
|
作者：
Sophie Broutin
Adam Stewart
Parames Thavasu
Angelo Paci
Jean-Michel Bidart
Udai Banerji
机构：
[1] Gustave Roussy,Département de Biologie et Pathologie Médicales
[2] Université Paris-Saclay,undefined
[3] Villejuif,undefined
[4] F-94805,undefined
[5] France,undefined
[6] The Institute of Cancer Research,undefined
[7] Clinical Pharmacology and Trials Team,undefined
来源：
British Journal of Cancer | 2016年 / 115卷
关键词：
drug combinations; NSCLC; KRAS mutant; MEK inhibitor; trametinib; m-TOR inhibitor; AZD2014;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：549 / 552
页数：3
相关论文
共 50 条
  • [31] KRAS-mutant non-small cell lung cancer: Converging small molecules and immune checkpoint inhibition
    Adderley, Helen
    Blackhall, Fiona H.
    Lindsay, Colin R.
    EBIOMEDICINE, 2019, 41 : 711 - 716
  • [32] MEK inhibitors under development for treatment of non-small-cell lung cancer
    Kim, Chul
    Giaccone, Giuseppe
    EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2018, 27 (01) : 17 - 30
  • [33] Prognostic and Predictive Value in KRAS in Non-Small-Cell Lung Cancer A Review
    Wood, Kevin
    Hensing, Thomas
    Malik, Raeva
    Salgia, Ravi
    JAMA ONCOLOGY, 2016, 2 (06) : 805 - 812
  • [34] Contributions of KRAS and RAL in Non-Small-Cell Lung Cancer Growth and Progression
    Guin, Sunny
    Ru, Yuanbin
    Wynes, Murry W.
    Mishra, Rangnath
    Lu, Xian
    Owens, Charles
    Baron, Anna E.
    Vasu, Vihas T.
    Hirsch, Fred R.
    Kern, Jeffrey A.
    Theodorescu, Dan
    JOURNAL OF THORACIC ONCOLOGY, 2013, 8 (12) : 1492 - 1501
  • [35] Intratumoral heterogeneity of KRAS mutation is rare in non-small-cell lung cancer
    Alsdorf, Winfried H.
    Clauditz, Till S.
    Hoenig, Tobias
    Quaas, Alexander
    Sirma, Hueseyin
    Koenig, Alexandra M.
    Izbicki, Jakob
    Sauter, Guido
    Marx, Andreas H.
    Grob, Tobias J.
    EXPERIMENTAL AND MOLECULAR PATHOLOGY, 2013, 94 (01) : 155 - 159
  • [36] Treatment Strategies for KRAS-Mutated Non-Small-Cell Lung Cancer
    O'Sullivan, Eabha
    Keogh, Anna
    Henderson, Brian
    Finn, Stephen P.
    Gray, Steven G.
    Gately, Kathy
    CANCERS, 2023, 15 (06)
  • [37] Future of ALK inhibition in non-small-cell lung cancer
    Reckamp, Karen L.
    LANCET ONCOLOGY, 2014, 15 (10): : 1047 - 1049
  • [38] The clinical relevance of KRAS gene mutation in non-small-cell lung cancer
    Timar, Jozsef
    CURRENT OPINION IN ONCOLOGY, 2014, 26 (02) : 138 - 144
  • [39] A differential analysis of TCR repertoire between patients with EGFR-mutant and KRAS-mutant non-small-cell lung cancer
    Xie, Yuancai
    Li, Yingmei
    Dong, Linfeng
    Chen, Shifu
    Liu, Jixian
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [40] Co-Inhibition of MEK/RTK Pathways Induces High Therapeutic Efficacy in Pan-KRAS-Mutant Non-Small Cell Lung Cancer
    Lu, J.
    Hu, M.
    Zhao, Y.
    Zhong, H.
    Ji, H.
    Han, B.
    JOURNAL OF THORACIC ONCOLOGY, 2024, 19 (10) : S309 - S310
12345